But, in patients without diabetes, preliminary studies suggest GLP-1 use could be associated with lower risk, although more research is needed 32
The Novo Nordisk-funded FLOW trial, published in the New England Journal of Medicine on 24 May 2024, randomly assigned patients with T2DM and CKD to receive subcutaneous semaglutide at a dose of 1.0mg weekly, or a placebo, to test whether treatment with semaglutide would mitigate the high risk for kidney failure, cardiovascular events and death
The redness comes from the needle causing minor tissue trauma and a small localized inflammatory response
Drugs ORAL HYPOGLYCEMICS: : glyburide, glipizide, glimepiride Sulfonylureas : repaglinide, nateglinide Glinides : metformin Biguanide : acarbose, miglitol -Glucosidase Inhibitors Thiazolidinediones or : pioglitazone, rosiglitazone Glitazones 1) : bromocriptine Dopamine agonist : canagliflozin, dapagliflozin, empagliflozin SGLT-2 Inhibitors : sitagliptin, saxagliptin, linagliptin, alogliptin DPP-IV Inhibitors INJECTIBLE HYPOGLYCEMICS : : exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide GLP-1 Agonists : pramlintide Amylin Analog BILE ACID SEQUESTRANTS: colesevelam INSULINS: PRANDIAL: : lispro, aspart, glulisine, inhaled Rapid acting : regular crystalline zinc Short-acting BASAL: : NPH (or Isophane) Intermediate acting : glargine, detemir Long acting : degludec Ultra-long acting INSULIN + GLP1 COMBINATIONS: glargine + lixisenatide (Soliqua ) degludec + liraglutide (Xultophy ) GOALS OF THERAPY Figure X
A dietitian explains how to keep the weight off Drugs.com (2023)
In the SURPASS-2 trial (published in The New England Journal of Medicine in 2021), tirzepatide at 5, 10, and 15 mg was compared with semaglutide 1 mg in 1,879 adults with type 2 diabetes on metformin over 40 weeks
